These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 23090602)
1. Antibiotics in phase II and III clinical trials. Coates AR; Halls G Handb Exp Pharmacol; 2012; (211):167-83. PubMed ID: 23090602 [TBL] [Abstract][Full Text] [Related]
2. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Falagas ME; Giannopoulou KP; Kokolakis GN; Rafailidis PI Clin Infect Dis; 2008 Apr; 46(7):1069-77. PubMed ID: 18444827 [TBL] [Abstract][Full Text] [Related]
4. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Leonard SN; Rybak MJ Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530 [TBL] [Abstract][Full Text] [Related]
5. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Garrison MW; Neumiller JJ; Setter SM Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603 [TBL] [Abstract][Full Text] [Related]
6. Tigecycline: clinical evidence and formulary positioning. Nathwani D Int J Antimicrob Agents; 2005 Mar; 25(3):185-92. PubMed ID: 15737510 [TBL] [Abstract][Full Text] [Related]
7. Will new antimicrobials overcome resistance among Gram-negatives? Bassetti M; Ginocchio F; Mikulska M; Taramasso L; Giacobbe DR Expert Rev Anti Infect Ther; 2011 Oct; 9(10):909-22. PubMed ID: 21973303 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
9. Antibiotic therapy for gram-negative bacteremia. Calandra T; Cometta A Infect Dis Clin North Am; 1991 Dec; 5(4):817-34. PubMed ID: 1783770 [TBL] [Abstract][Full Text] [Related]
10. New antibiotic agents for bloodstream infections. Vergidis PI; Falagas ME Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms. Hagihara M; Crandon JL; Nicolau DP Expert Opin Drug Saf; 2012 Mar; 11(2):221-33. PubMed ID: 22074343 [TBL] [Abstract][Full Text] [Related]
12. Fighting infections due to multidrug-resistant Gram-positive pathogens. Cornaglia G Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367 [TBL] [Abstract][Full Text] [Related]
13. Tigecycline: a novel glycylcycline antibiotic. Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206 [TBL] [Abstract][Full Text] [Related]
15. What is in the pipeline for Gram-negative pathogens? Talbot GH Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663 [TBL] [Abstract][Full Text] [Related]
16. Teicoplanin in the therapy of gram-positive infections: an open non-randomized study. De Lalla F; Rinaldi E; Santoro D; Rizzardini G; Martello P; Guaglianone MH J Chemother; 1989 Jul; 1(4 Suppl):719-21. PubMed ID: 16312606 [No Abstract] [Full Text] [Related]
17. Rifampicin combined regimens for gram-negative infections: data from the literature. Drapeau CM; Grilli E; Petrosillo N Int J Antimicrob Agents; 2010 Jan; 35(1):39-44. PubMed ID: 19815392 [TBL] [Abstract][Full Text] [Related]